DK2564846T3 - Fremgangsmåder til behandling af hæmatologiske cancer-former under anvendelse af PNP-inhibitorer såsom Forodesin i kombination med anti-CD20-midler - Google Patents
Fremgangsmåder til behandling af hæmatologiske cancer-former under anvendelse af PNP-inhibitorer såsom Forodesin i kombination med anti-CD20-midler Download PDFInfo
- Publication number
- DK2564846T3 DK2564846T3 DK12177257.8T DK12177257T DK2564846T3 DK 2564846 T3 DK2564846 T3 DK 2564846T3 DK 12177257 T DK12177257 T DK 12177257T DK 2564846 T3 DK2564846 T3 DK 2564846T3
- Authority
- DK
- Denmark
- Prior art keywords
- forodesine
- rituximab
- alkylating agent
- combination
- forodesin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (21)
1. Anvendelse af Forodesin i kombination med Rituximab i fremstillingen af et medikament til behandling af hæmatologisk cancer.
2. Anvendelse ifølge krav 1, hvor Forodesin og Rituximab administreres samtidigt eller sekventielt.
3. Anvendelse ifølge et hvilket som helst af kravene 1 eller 2, hvor Rituximab administreres én eller flere gange før administration af Forodesin.
4. Anvendelse ifølge et hvilket som helst af kravene 1 til 3, yderligere omfattende et alkyleringsmiddel.
5. Anvendelse ifølge krav 4, hvor alkyleringsmidlet administreres én eller flere gange før administration af Forodesin.
6. Forodesin i kombination med Rituximab, til anvendelse i behandlingen af hæmatologisk cancer.
7. Forodesin i kombination med Rituximab, til anvendelse ifølge krav 6, hvor Forodesin og Rituximab administreres samtidigt eller sekventielt.
8. Forodesin i kombination med Rituximab, til anvendelse ifølge enten krav 6 eller krav 7, hvor Rituximab administreres én eller flere gange før administration af Forodesin.
9. Forodesin i kombination med Rituximab til anvendelse ifølge et hvilket som helst af kravene 6 til 8, yderligere omfattende et alkyleringsmiddel.
10. Forodesin i kombination med Rituximab, til anvendelse ifølge krav 9, hvor alkyleringsmidlet administreres én eller flere gange før administration af Forodesin.
11. Anvendelse ifølge et hvilket som helst af kravene 1 to 5, eller en kombination til anvendelse ifølge et hvilket som helst af kravene 6 til 10, hvor den hæmatologiske cancer er valgt fra kronisk lymfocytisk leukæmi, akut lymfoblastisk leukæmi og non-Hodgkin's lymfom.
12. Anvendelse eller en kombination til anvendelse ifølge krav 11, hvor den hæmatologiske cancer er kronisk lymfocytisk leukæmi.
13. Anvendelse ifølge et hvilket som helst af kravene 4 og 5 eller en kombination til anvendelse ifølge et hvilket som helst af kravene 9 og 10, hvor alkyleringsmidlet er valgt fra: et sennepsderivat, et nitrosoureaderivat, en platinforbindelse, og en imidazolcarboxamidforbindelse.
14. Anvendelse ifølge et hvilket som helst af kravene 4 og 5, eller en kombination til anvendelse ifølge et hvilket som helst af kravene 9 og 10, hvor alkyleringsmidlet er Bendamustin.
15. Farmaceutisk sammensætning omfattende Forodesin og Rituximab.
16. Farmaceutisk sammensætning ifølge krav 15, yderligere omfattende et alkyleringsmiddel.
17. Kit omfattende Forodesin og Rituximab.
18. Kit ifølge krav 17, yderligere omfattende et alkyleringsmiddel.
19. Kit ifølge et hvilket som helst af krav 17 eller krav 18, yderligere omfattende et leveringssystem til Forodesin, Rituximab, det eventuelle alkyleringsmiddel, eller en hvilken som helst kombination deraf, hvilket kit eventuelt yderligere omfatter instruktioner til behandling af individet.
20. Farmaceutisk sammensætning ifølge krav 16 eller et kit ifølge enten krav 18 eller krav 19, hvor alkyleringsmidlet er valgt fra: et sennepsderivat, et nitrosoureaderivat, en platinforbindelse, og en imidazolcarboxamidforbindelse.
21. Farmaceutisk sammensætning ifølge krav 16 eller et kit ifølge enten krav 18 eller krav 19, hvor alkyleringsmidlet er Bendamustin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1276207P | 2007-12-10 | 2007-12-10 | |
| EP08860419A EP2237778A2 (en) | 2007-12-10 | 2008-12-10 | Methods of treating hematologic cancers using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2564846T3 true DK2564846T3 (da) | 2018-05-22 |
Family
ID=40431122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12177257.8T DK2564846T3 (da) | 2007-12-10 | 2008-12-10 | Fremgangsmåder til behandling af hæmatologiske cancer-former under anvendelse af PNP-inhibitorer såsom Forodesin i kombination med anti-CD20-midler |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20110038858A1 (da) |
| EP (3) | EP2237778A2 (da) |
| JP (2) | JP5543362B2 (da) |
| KR (1) | KR101545367B1 (da) |
| CN (2) | CN103736091B (da) |
| AU (1) | AU2008335167B2 (da) |
| CA (2) | CA2881035C (da) |
| CY (1) | CY1120203T1 (da) |
| DK (1) | DK2564846T3 (da) |
| EA (2) | EA025340B1 (da) |
| ES (1) | ES2670714T3 (da) |
| GE (2) | GEP20135855B (da) |
| HR (1) | HRP20180712T1 (da) |
| HU (1) | HUE037342T2 (da) |
| IL (1) | IL206264A (da) |
| LT (1) | LT2564846T (da) |
| MY (2) | MY193789A (da) |
| NO (1) | NO2564846T3 (da) |
| NZ (3) | NZ601072A (da) |
| PH (1) | PH12014501454A1 (da) |
| PL (1) | PL2564846T3 (da) |
| PT (1) | PT2564846T (da) |
| SG (1) | SG188870A1 (da) |
| SI (1) | SI2564846T1 (da) |
| UA (2) | UA104579C2 (da) |
| WO (1) | WO2009076455A2 (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9452217B2 (en) | 2013-06-22 | 2016-09-27 | Nitor Therapeutics | Methods for potentiating immune response for the treatment of infectious diseases and cancer |
| US20170209447A1 (en) * | 2014-08-07 | 2017-07-27 | Nitor Therapeutics | Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US199697A (en) | 1878-01-29 | Improvement in butter-sharers | ||
| ATE157363T1 (de) | 1989-02-27 | 1997-09-15 | Biocryst Pharm Inc | 9-substituierte-8-unsubstituierte-9-deazaguanin |
| US4985434A (en) | 1989-10-31 | 1991-01-15 | Biocryst, Inc. | 7-substituted derivatives of 2-amino-3H,5H-pyrrolo(3,2-d)pyrimidin-4-ones and pharamceutical uses and compositions containing the same |
| US4985433A (en) | 1989-10-31 | 1991-01-15 | Biocryst, Inc. | 2-amino-7-(pyridinylmethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same |
| US5008265A (en) | 1989-10-31 | 1991-04-16 | Biocryst, Inc. | 2-amino-7-(alicyclomethyl)-3H,5H,-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same |
| US5008270A (en) | 1989-10-31 | 1991-04-16 | Biocryst, Inc. | 2-amino-7-(heterocyclomethyl)-3H,5H-pyrrolo[3,2-d]pyrimidin-4-ones and pharmaceutical uses and compositions containing the same |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1996011200A1 (en) | 1994-10-05 | 1996-04-18 | Chiroscience Limited | Purine and guanine compounds as inhibitors of pnp |
| PT2055313E (pt) | 1998-11-09 | 2015-08-25 | Biogen Idec Inc | Tratamento de malignidades hematológicas associadas a células tumorais em circulação utilizando anticorpo quimérico anti-cd20 |
| US6387923B2 (en) * | 2000-03-22 | 2002-05-14 | Biocryst Pharmacueticals, Inc. | Imminoribitol PNP inhibitors, preparation thereof and use thereof |
| DE10306724A1 (de) * | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
| EP2272512A1 (en) | 2002-05-17 | 2011-01-12 | Celgene Corporation | Pharmaceutical compositions for treating cancer |
| EP2336141B1 (en) * | 2005-06-29 | 2016-03-30 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
-
2008
- 2008-10-12 UA UAA201008568A patent/UA104579C2/uk unknown
- 2008-12-10 CA CA2881035A patent/CA2881035C/en not_active Expired - Fee Related
- 2008-12-10 PL PL12177257T patent/PL2564846T3/pl unknown
- 2008-12-10 AU AU2008335167A patent/AU2008335167B2/en active Active
- 2008-12-10 ES ES12177257.8T patent/ES2670714T3/es active Active
- 2008-12-10 EP EP08860419A patent/EP2237778A2/en not_active Withdrawn
- 2008-12-10 EP EP12177257.8A patent/EP2564846B1/en active Active
- 2008-12-10 WO PCT/US2008/086256 patent/WO2009076455A2/en active Application Filing
- 2008-12-10 NZ NZ601072A patent/NZ601072A/en unknown
- 2008-12-10 UA UAA201311750A patent/UA109571C2/uk unknown
- 2008-12-10 LT LTEP12177257.8T patent/LT2564846T/lt unknown
- 2008-12-10 CA CA2708606A patent/CA2708606C/en active Active
- 2008-12-10 SG SG2013017215A patent/SG188870A1/en unknown
- 2008-12-10 EP EP12196293.0A patent/EP2581083A1/en not_active Withdrawn
- 2008-12-10 GE GEAP200811877A patent/GEP20135855B/en unknown
- 2008-12-10 EA EA201370055A patent/EA025340B1/ru not_active IP Right Cessation
- 2008-12-10 NZ NZ586416A patent/NZ586416A/en not_active IP Right Cessation
- 2008-12-10 CN CN201410039689.9A patent/CN103736091B/zh active Active
- 2008-12-10 CN CN200880126808.7A patent/CN101969947B/zh active Active
- 2008-12-10 MY MYPI2014002587A patent/MY193789A/en unknown
- 2008-12-10 GE GEAP200812864A patent/GEP20156288B/en unknown
- 2008-12-10 HU HUE12177257A patent/HUE037342T2/hu unknown
- 2008-12-10 MY MYPI2010002665A patent/MY163023A/en unknown
- 2008-12-10 US US12/747,456 patent/US20110038858A1/en not_active Abandoned
- 2008-12-10 NO NO12177257A patent/NO2564846T3/no unknown
- 2008-12-10 EA EA201070669A patent/EA018415B1/ru not_active IP Right Cessation
- 2008-12-10 NZ NZ617989A patent/NZ617989A/en not_active IP Right Cessation
- 2008-12-10 JP JP2010537159A patent/JP5543362B2/ja active Active
- 2008-12-10 DK DK12177257.8T patent/DK2564846T3/da active
- 2008-12-10 KR KR1020107015164A patent/KR101545367B1/ko active IP Right Grant
- 2008-12-10 SI SI200831952T patent/SI2564846T1/en unknown
- 2008-12-10 PT PT121772578T patent/PT2564846T/pt unknown
-
2010
- 2010-06-09 IL IL206264A patent/IL206264A/en active IP Right Grant
-
2014
- 2014-01-22 JP JP2014009359A patent/JP2014094962A/ja not_active Withdrawn
- 2014-02-26 US US14/190,987 patent/US20140178372A1/en not_active Abandoned
- 2014-06-24 PH PH12014501454A patent/PH12014501454A1/en unknown
-
2018
- 2018-05-07 HR HRP20180712TT patent/HRP20180712T1/hr unknown
- 2018-05-14 CY CY20181100492T patent/CY1120203T1/el unknown
-
2019
- 2019-05-01 US US16/400,414 patent/US11110092B2/en active Active
-
2021
- 2021-08-04 US US17/393,897 patent/US20220040188A1/en not_active Abandoned
-
2023
- 2023-11-01 US US18/386,050 patent/US20240100055A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240100055A1 (en) | Methods of treating hematologic cancers | |
| Saha et al. | MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity | |
| EP3835323A1 (en) | Combination therapy for cancer | |
| RU2765997C2 (ru) | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования | |
| JP2020517640A5 (da) | ||
| US20170306050A1 (en) | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases | |
| JP2023182572A (ja) | がんの診断及び治療方法 | |
| JP2019512271A (ja) | Ｔ細胞疲弊状態特異的遺伝子発現調節因子およびその使用 | |
| WO2021127217A1 (en) | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly | |
| AU2013201347B2 (en) | Methods of treating hematologic cancers | |
| WO2024108256A1 (en) | Compositions and methods for improved cancer treatment |